Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study

Neurology

Volumn 60, Issue 4, 2003, Pages 601-605

  Doder, M ^a,b,c   Rabiner, E A ^a   Turjanski, N ^a   Lees, A J ^b   Brooks, D J ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CARBON 11; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PERGOLIDE; ROPINIROLE; SEROTONIN 1A RECEPTOR;

ADULT; AGED; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; HUMAN; LEWY BODY; MESENCEPHALON; NEUROTRANSMISSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIGIDITY; SEROTONINERGIC SYSTEM; TREMOR;

EID: 0037465371     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000031424.51127.2B     Document Type: Article

References (45)

1. Rajput AH. Clinical features of tremor in extrapyramidal syndromes. In: Findley LJ, Koller WC, eds. Handbook of tremor disorders. New York: Marcel Dekker, 1995;275-291.
2. Koller WC, Hubble JP. Levodopa therapy in Parkinson's disease. Neurology 1990;40(suppl 3):40-47.
3. 18F-Dopa PET study. Neurology 1992;42:1554-1560.
4. 123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-1228.
5. Wilms H, Sievers J, Deuschl G. Animal models of tremor. Mov Disord 1999;4:557-571.
6. Ward AA, McCullough WS, Magpun HW. Production of alternating tremor at rest in monkeys. J Neurophysiol 1948;11:317-330.
7. Poirier LJ. Experimental and histological study of midbrain dyskinesia. J Neuropsychol 1960;23:534-551.
8. Goldstein M, Battista AF, Nakatani S, Anagoste B. The effects of centrally acting drugs on tremor in monkeys with mesencephalic lesions. Proc Natl Acad Sci USA 1969;63:1113-1116.
9. Velasco F, Velasco M, Romo R, Maldonaldo H. Production and suppression of tremor by mesencephalic tegmental lesions in monkeys. Exp Neurol 1979;64:516-527.
10. Ohmoto T. Experimental study of resting tremor and L-dopa-induced dyskinesia. Eur Neurol 1987;26(suppl 1):47-55.
11. Kaelber WW. Tremor at rest from tegmental lesions in the cat. J Neuropathol Exp Neurol 1963;22:695-701.
12. 14C]serotonin in the striatum. J Neurochem 1969;16:645-653.
13. Lamarre Y. Central mechanisms of experimental tremor and their clinical relevance. In: Findley LJ, Koller WC, eds. Handbook of tremor disorders. New York: Marcel Dekker, 1995;103-118.
14. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1986;45:1-18.
15. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brain stem neurons in Parkinson's disease. Ann Neurol 1990;27:373-385.
16. Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB. Loss of brain stem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510:104-107.
17. Scatton B, Javoy-Agid F, Montfort JC, Agid Y. Neurochemistry of monoaminergic neurons in Parkinson's disease. In: Usdin E, Carlsson A, Dahlstrom A, Engel J, eds. Neuropharmacology and central nervous system: therapeutic aspects. New York: Alan R. Liss, 1984;43-52.
18. Bernheimer H, Birkmayer W, Hornykiewicz O. Verteilung des 5-hydroxytryptamin (serotonin) im gehirn des menschen und sein verhalten bei patienten mit Parkinson-syndrome. Klin Wochenschr 1961;39:1056-1059.
19. 11C]WAY-100635. Brain Res 1997;745:96-108.
20. Rinne UK, Koskinen U, Lonnberg P. Neurotransmitter receptors in the parkinsonian brain. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier North-Holland Press, 1980:93-107.
21. 2A receptors are increased in Parkinson's disease neocortex. Ann NY Acad Sci 1998;861:288-289.
22. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997;6:279-287.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association, 1994.
25. Mahieux F, Michelet D, Manifacier MJ, Boller F, Fermanian J, Guillard A. Mini-Mental Parkinson. First validation study of a new bedside test constructed for Parkinson's disease. Behav Neurol 1995;8:15-22.
26. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage 1996;4:153-158.
27. Studholme C, Hill LG, Howkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Psych 1997;24:25-35.
28. 1A receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology 2000;23:287-293.
29. Hammers A, Koepp MJ, Free SL, et al. Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp 2002;15:165-174.
30. Meyer J, Gunn R, Myers R, Grasby P. Assessment of spatial normalisation of PET ligand images using ligand specific templates. NeuroImage 1999;9:545-553.
31. 1A receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. NeuroImage 2002;15:620-632.
32. 11C]WAY 100635. Brain Res 1998;745:106-108.
33. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 1995;118:1447-1459.
34. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
35. 3H-imipramine binding in Parkinson's disease. Biol Psychiatry 1988;24:348-351.
36. 3H-paroxetine binding sites in putamen. Neurology 1986;36:556-560.
37. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998;51(suppl 2):S2-S9.
38. 11C]WAY-100635. Effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:2174-2180.
39. Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neurosci 1993;16:346-352.
40. De Deurwaerdere P, Bonhomme N, Lucas G, Le Moal M, Spampinato U. Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem 1996;66:210-215.
41. Barbeau A. The pathogenesis of Parkinson's disease. A new hypothesis. Can Med Assoc J 1962;87:802-807.
42. Jansen Steur ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-213.
43. Meltzer HY, Fang VS. Effect of apomorphine plus 5-hydroxytryptophan on plasma prolactin levels in male rats. Psychopharmacol Commun 1976;2:189-198.
44. Sasaki-Adams DM, Kelley AE. Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology 2001;25:440-452.
45. Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 1991;200:1-8.